FDA Approves First Oral IL-23 Inhibitor for Psoriasis, Ending the Needle for Millions of Patients
Johnson & Johnson's Icotyde (icotrokinra), a once-daily oral peptide that blocks the IL-23 receptor, became the first targeted oral therapy to match biologic-level skin clearance in moderate-to-severe plaque psoriasis, marking a potential paradigm shift away from injectable treatments.
3 min read3 sources